Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » MBHS NEWS

 - UBBFriend: Email this page to someone!    
Author Topic: MBHS NEWS
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
News after the bell today. Company has been quiet lately. Looks like its coming back into play with some good news and an update on what the company is currently doing and how they are protecting our investments in the international market. Here is the complete news...



mBeach Software Inc. Targets New International Markets: Extends Global Patent Protection

TEL AVIV, Israel, Aug 18, 2010 (GlobeNewswire via COMTEX) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced the filing of additional patent applications under the framework of the Patent Cooperation Treaty (PCT). This move will facilitate the company's strategy to enter new international markets for its advanced, non-invasive system to detect and identify skin cancer.

Skin Cancer Scanning Ltd. ("SCS"), the wholly owned subsidiary, has already submitted a patent application in the United States (application number 11/464,838) with a priority date of August 2006. The patent office is currently examining this application and the company expects the patent to be approved and published by the end of 2010.

In addition to the United States, SCS has filed patent applications in many important markets around the world. These countries include Canada, Japan, Australia, China, South Korea, Singapore, New Zealand, Israel, South Africa, Brazil, Mexico, Russia and the Commonwealth of Independent States (CIS), Ukraine, and the European Union. These patent applications have now reached the national phase of registration.

"Our intellectual property is one of the company's most valuable assets," said mBeach CEO Yossi Biderman. "We are taking all necessary measures to protect this asset, including patent applications and other appropriate actions. International growth is an important part of our strategy for growth. We want to make sure we have the right patent protection in all our major potential markets as soon as possible."

Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
TEL AVIV, Israel, Aug. 20, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

We have identified the Japanese, Hi-Tech orientated market, as a potential pivotal market, with increasing awareness to skin cancer related issues in the past decade.

Total population of Japan exceeds 125 million people, and there is increasing demand for advanced medical technologies.

The number of patients with malignant skin tumors has increased year by year.

The annual increase of deaths from Non Melanoma Skin Cancer (NMSC) is 3.8%. (Hisashi Ohtsukaa, Shogo Nagamatsub).

Early detection is critical to survival, and can lead to almost a one hundred percent cure rate. However, the effectiveness of current cancer detection procedures is heavily dependent on the experience of the examiner, and errors in diagnosis can be fatal. Occasionally, cancers remained undetected, grow further and lead to lower chances of survival. An additional disadvantage with current diagnostic methods is that they rely on a biopsy, the intrusive removal of tissue sample, to confirm the presence of cancerous tissue.

Biopsies can be painful, leave scarring, and often cause unnecessary patient anxiety.

SCS is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.

mBeach CEO Yossi Biderman commented," The Japanese market and other intended market surveys are being initiated at these early stages due to the lengthy regulatory procedures in each country, before receiving marketing approval. We expect initial approvals to coincide with industrial device following clinical trials, during 2011".

Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
TEL AVIV, Israel, Aug. 20, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update on the growing market for skin cancer diagnostic solutions. These market developments represent significant opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

We have identified the Japanese, Hi-Tech orientated market, as a potential pivotal market, with increasing awareness to skin cancer related issues in the past decade.

Total population of Japan exceeds 125 million people, and there is increasing demand for advanced medical technologies.

The number of patients with malignant skin tumors has increased year by year.

The annual increase of deaths from Non Melanoma Skin Cancer (NMSC) is 3.8%. (Hisashi Ohtsukaa, Shogo Nagamatsub).

Early detection is critical to survival, and can lead to almost a one hundred percent cure rate. However, the effectiveness of current cancer detection procedures is heavily dependent on the experience of the examiner, and errors in diagnosis can be fatal. Occasionally, cancers remained undetected, grow further and lead to lower chances of survival. An additional disadvantage with current diagnostic methods is that they rely on a biopsy, the intrusive removal of tissue sample, to confirm the presence of cancerous tissue.

Biopsies can be painful, leave scarring, and often cause unnecessary patient anxiety.

SCS is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.

mBeach CEO Yossi Biderman commented," The Japanese market and other intended market surveys are being initiated at these early stages due to the lengthy regulatory procedures in each country, before receiving marketing approval. We expect initial approvals to coincide with industrial device following clinical trials, during 2011".

Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
JFPENNY
Member


Rate Member
Icon 1 posted      Profile for JFPENNY     Send New Private Message       Edit/Delete Post   Reply With Quote 
Not too bad of a day here on MBHS, Company had news at the close and it explains a little about there marketing strategy. Charts look good on this one. We have .0006 as a support and a slight resistance at .0008 which could be broken. The next resistance is at .0011. This one could easily run. Keep you eyes peeled.



mBeach Software Inc. Defining Marketing Strategy for Non-Intrusive Technologies for the Detection of Skin Cancer

TEL AVIV, Israel, Aug 23, 2010 (GlobeNewswire via COMTEX) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today issued a stockholder update on its Evolving Marketing Strategy for skin cancer diagnostic solutions. The adopted strategy represents an entrepreneurial concept approach to locating and initiating opportunities for the wholly owned subsidiary, Skin Cancer Scanning Ltd. ("SCS") to grow the company and become a leading industry player.

The initially targeted countries are the USA, Russia and the CIS, Australia, Germany, Japan, and Israel.

The Basic Strategy concept is a four pillar structure: Preliminary logistics for initiation and maintenance of service for large volume of demand for the device; Advanced survey to define all relevant aspects (Production, Distribution, Tech Support); Survey of the specific targeted regions; Locate and engage a distributor, meeting with the requirements, in the defined country/state/ region.

The marketing strategy in every country will be basically similar and will be executed in similar initial stages. The differences will be the result of health reimbursement programs, Medicare concept, and conduct of distribution and use of medical devices.

mBeach is clearly focused on meeting this growing market need for a safe, non-intrusive technology to detect skin cancer.

mBeach CEO Yossi Biderman commented, "The marketing strategy we have defined at this early stage is due to the lengthy regulatory procedures in each country. We expect that the mutual impact of market demand and technical innovative approach on the final product will result in what we think will be a most advanced, adaptable, and technically supported, medical device for the early detection of skin cancer. We expect our SkinScan 650, a non-invasive, point-of-care, doctors' decision supporting device, to provide the Medical practitioner a much needed user friendly diagnostic solution."

Posts: 221 | Registered: Sep 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
TEL AVIV, Israel, Aug. 30, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News), in accordance with company policy which recognizes the importance of regular communication and timely information delivered to investors, is committed to share with our stockholders regular updates on progress. We have received recent progress reports from our Russian counterpart as to the regulatory activities being undertaken by him since the signing of the MOU.


These regulatory procedures, which take some time to consummate, are basic necessary factors that need to be executed in order to conduct clinical trials and to proceed marketing the company's advanced cancer diagnostic solution in Russia. This follows the mBeach recent announcement on the signing of an MOU for Russia and the Commonwealth of Independent States (CIS).


Completing these regulatory procedures will pave the way for local clinical trials and a full commercial launch of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers. SCS expects to receive the initial import approval by the end of October 2010.


mBeach CEO Yossi Biderman commented, "We are impressed by our Russian business associate in his execution of the MOU terms and are excited at the prospects of entering this very large and attractive region, one of the fastest-growing healthcare markets in the world. Typically in Russia today, cancer is diagnosed at relatively advanced stages when treatment options are less effective and more costly. Our market research identifies a clear demand for advanced medical technologies such as ours for the early detection of skin cancer." Mr. Biderman further stated, "We will be working closely with our local distributor and look forward to updating our shareholders on our progress in this important market."


About SCS


Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.


Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.


For more information on SCS, visit www.scs-med.com.


Forward Looking Statements


This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
mickymoose99
Member


Member Rated:
5
Icon 1 posted      Profile for mickymoose99     Send New Private Message       Edit/Delete Post   Reply With Quote 
mBeach Software Inc. Issues Stockholder Update
.
Companies:MBEACH SOFTWARE INC.Related Quotes
Symbol Price Change
MBHS.OB 0.32 +0.03


{"s" : "mbhs.ob","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: mBeach Software Inc. On Tuesday September 7, 2010, 4:00 pm EDT

TEL AVIV, Israel, Sept. 7, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today issued a stockholder update. The Company believes in the importance of regular communication and timely information delivered to investors. To this end, mBeach is committed to share with its stockholders release regular updates on its progress.


mBeach, through its wholly owned subsidiary Skin Cancer Scanning Ltd. ("SCS") is pioneering the development and commercialization of a revolutionary and proprietary diagnostic device for the early detection and diagnosis of skin cancer. Our product, an advanced stage prototype, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers.


To date, we have successfully conducted two stages of clinical trials. The results from 128 scanned nevi demonstrated 92.4% accuracy in diagnosing non-melanoma skin cancer (NMSC). These results are significantly higher than the 75% accuracy achieved by an experienced dermatologist and 60% accuracy achieved by a general practitioner.


These initial results were gained by operating the device in the visual range (the light that we can see with an unaided eye) of the light spectrum.


We expect that further development of the devices' capabilities, into the Infra Red range, will dramatically improve results in diagnosing both Melanoma and Non Melanoma Skin Cancer.


We intend to complete the second stage development by July 2011. This will enable us to introduce into the market our SkinScan 650 diagnostic device with its full capabilities.


Our medical device, SkinScan 650's state-of-the-art technology will enable physicians to improve their diagnostic abilities using SkinScan 650. This will replace current diagnostic procedures that have many disadvantages, such as being relatively subjective and dependent on the experience of the examiner. Errors in diagnosis can be fatal. Cancers can remain undetected, grow further and lower chances of survival. A biopsy, the intrusive removal of tissue sample, is usually needed for further diagnoses.


For more information on SCS, visit the company's new website at www.scs-med.com

Posts: 141 | From: new jersey | Registered: Oct 2009  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share